title: British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.
authors.affiliation: St John's Institute of Dermatology, GKT School of Medicine, St Thomas' Hospital, London SE1 7EH, UK. Catherine.smith@kcl.ac.uk
authors.forename: C H
authors.initials: CH
authors.lastname: Smith
authors.forename: A V
authors.initials: AV
authors.lastname: Anstey
authors.forename: J N W N
authors.initials: JN
authors.lastname: Barker
authors.forename: A D
authors.initials: AD
authors.lastname: Burden
authors.forename: R J G
authors.initials: RJ
authors.lastname: Chalmers
authors.forename: D
authors.initials: D
authors.lastname: Chandler
authors.forename: A Y
authors.initials: AY
authors.lastname: Finlay
authors.forename: C E M
authors.initials: CE
authors.lastname: Griffiths
authors.forename: C E M
authors.initials: CE
authors.lastname: Grifitths
authors.forename: K
authors.initials: K
authors.lastname: Jackson
authors.forename: N J
authors.initials: NJ
authors.lastname: McHugh
authors.forename: K E
authors.initials: KE
authors.lastname: McKenna
authors.forename: N J
authors.initials: NJ
authors.lastname: Reynolds
authors.forename: A D
authors.initials: AD
authors.lastname: Ormerod
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens / Q000276:immunology; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D018579:Patient Selection; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012074:Remission Induction; D012306:Risk; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept; C472181:efalizumab